Corporate Member Update- Genentech
Corporate Member Update- Genentech
Itovebi (inavolisib)
November, 2024
NOW APPROVED
- In combination with palbociclib and fulvestrant
- For 1L HR+/HER2- mBC
- With PIK3CA mutation and endocrine resistance
Indication
Itovebi (inavolisib), in combination with palbociclib and fulvestrant, is indicated for the treatment of adults with endocrine-resistant, PIK3CA-mutated, hormone receptor (HR)-positive, human epidermal growth-factor receptor 2 (HER2)-negative, locally advanced or metastatic breast cancer, as detected by an FDA-approved test, following recurrence on or after completing adjuvant endocrine therapy.
To access the entire packet, please click here!
